Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hepatitis C 2Waldenstrom Macroglobulinemia 1Virus Diseases 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Liver Diseases 1Hepatitis C, Chronic 1

Interventions

Rituximab 57Cyclophosphamide 42fludarabine phosphate 29Peripheral Blood Stem Cell Transplantation 29Mycophenolic Acid 22Dexamethasone 21Tacrolimus 20Whole-Body Irradiation 18Bortezomib 18Cyclosporine 15Busulfan 13ibrutinib 12Methotrexate 12Melphalan 12Radiotherapy 11Etoposide 11Antilymphocyte Serum 10zanubrutinib 9Calcium Dobesilate 9venetoclax 7Sirolimus 7idelalisib 6Prednisone 6Lenalidomide 6Filgrastim 6Doxorubicin 6Cyclosporins 6Bendamustine Hydrochloride 6Alemtuzumab 6sargramostim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Waldenstrom Macroglobulinemia × ledipasvir, sofosbuvir drug combination × Clear all
NCT03261349 2017-08-25

Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma

National Taiwan University Hospital

Phase 2 Unknown
21 enrolled
Lymphoid

Hepatitis C, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡